Pioglitazona (Pioglitazone) API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

Produced in:

China

Established in: 2011

MOQ: 100 g

Employees: 10+

Fast Response and Good Communication

Willingness To Start From Small

Flexible Payment Terms

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • BSE/TSE

  • MSDS

Producer

Produced in:

India

Established in: 2021

MOQ: -

Employees: 19

API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides

Small quantity APIs to commercial scale

GMP and USFDA certification based on quantity, order, assignment.

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

  • FDA

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • KDMF

  • GMP

  • FDA

  • coa

Producer

Produced in:

Unknown

Established in: 1944

MOQ: -

Employees: 4,000

14 international API plant sites

Portfolio of 350+ APIs

Teva is among the world’s largest generic drug/API manufacturers

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • WC

  • CEP

  • FDA

  • coa

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • KDMF

  • GMP

  • WC

  • DMF

  • FDA

Contact supplier

Replies slower than most

Located in:

Japan

Produced in:

Japan

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • JDMF

  • CoA

Located in:

South Korea

Produced in:

South Korea

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • JDMF

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • DMF

  • WHO-GMP

Located in:

South Korea

Produced in:

South Korea

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • JDMF

  • CoA

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • coa

Located in:

Mexico

Producer

Produced in:

Mexico

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Producer

Produced in:

India

Established in: 1984

MOQ: -

Employees: 21,650

Diverse portfolio of 180+APIs

1754+ DMF across global markets

1100+ patents filed, and more than 70 own patents granted

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CEP

  • JDMF

  • WC

  • GMP

  • CoA

  • EDMF/ASMF

  • FDA

  • MSDS

  • BSE/TSE

Producer

Produced in:

India

Established in: 1995

MOQ: -

Employees: 10000

Fermentation technology Experts

Partnerships with 1200 pharma companies in 100+ countries

US FDA, EMA, COFEPRIES, ANVISA, PMDA accreditations

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • FDA

  • coa

  • KDMF

  • DMF

  • CEP

  • WC

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • CoA

  • GMP

  • JDMF

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • WC

  • DMF

  • CoA

Located in:

Italy

Producer

Produced in:

Italy

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • FDA

  • CEP

  • WC

  • DMF

  • coa

  • KDMF

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • CEP

  • WC

  • DMF

  • JDMF

  • GMP

  • FDA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Pioglitazone API 111025-46-8?

Description:
Here you will find a list of producers, manufacturers and distributors of Pioglitazone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Pioglitazone 
Synonyms:
Pioglitazona , Pioglitazone , Pioglitazonum , Pioglitazone hydrochloride  
Cas Number:
111025-46-8 
DrugBank number:
DB01132 
Unique Ingredient Identifier:
X4OV71U42S

About Pioglitazone

Some technical information about this product: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose4 via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.

g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Check who is selling Pioglitazone in the overview above.

Pioglitazone is a type of Glitazones


Glitazones, also known as thiazolidinediones (TZDs), are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of type 2 diabetes mellitus. These compounds act as insulin sensitizers, enhancing the body's response to insulin, thereby promoting glucose utilization and regulating blood sugar levels.

Glitazones exert their therapeutic effects by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor found predominantly in adipose tissue. PPAR-γ activation leads to improved insulin sensitivity in adipocytes, skeletal muscle cells, and hepatocytes, resulting in decreased hepatic glucose production and increased glucose uptake in peripheral tissues.

The primary glitazone medications available in the market include rosiglitazone and pioglitazone. These drugs are administered orally and are typically prescribed in conjunction with other antidiabetic medications, such as metformin or sulfonylureas, to achieve optimal glycemic control.

Glitazones are characterized by their high specificity for PPAR-γ receptors, which distinguishes them from other antidiabetic drug classes. However, their use may be associated with certain adverse effects, such as weight gain, fluid retention, and an increased risk of heart failure. Therefore, close monitoring and individual patient assessment are essential when prescribing glitazones.

In conclusion, glitazones are a valuable class of pharmaceutical APIs utilized in the management of type 2 diabetes. Their ability to enhance insulin sensitivity through PPAR-γ activation makes them an effective therapeutic option, albeit with potential side effects that require careful consideration in clinical practice.


Pioglitazone (Glitazones), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Pioglitazone manufacturers | traders | suppliers

We have 22 companies offering Pioglitazone produced in 7 different countries.

Get in contact with the supplier of your choice:

  • Shandong Octagon Chemicals Limited from China, product country of origin China
  • SETV Global from India, product country of origin India
  • Ind-Swift Labs. from India, product country of origin India
  • Teva API from Israel, product country of origin Unknown
  • Zhejiang Hisun Pharma from China, product country of origin China
  • Zhejiang Huayi from China, product country of origin China
  • USV from India, product country of origin India
  • Sumitomo Chemical from Japan, product country of origin Japan
  • Hanmi Fine Chemical from South Korea, product country of origin South Korea
  • JPN Pharma from India, product country of origin India
  • Inist St Co. from South Korea, product country of origin South Korea
  • Aarambh Life Science from India, product country of origin India
  • Signa from Mexico, product country of origin Mexico
  • Dr. Reddy's from India, product country of origin India
  • Biocon from India, product country of origin India
  • Hetero Drugs from India, product country of origin India
  • Mylan from India, product country of origin India
  • Erregierre from Italy, product country of origin Italy
  • Cipla from India, product country of origin India
  • MSN Organics from India, product country of origin India
  • Hetero Labs from India, product country of origin India
  • Lupin from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.